KRAS and non-small cell lung carcinoma: Despite this, several KRAS-binding small molecules (e.g., Sotorasib, Adagrasib) have been recently developed to irreversibly inhibit the G12C missense mutant of KRAS, showing encouraging results in various cancer types, including non-small cell lung cancer.